These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38348048)

  • 21. Non-neoplastic cells as prognostic biomarkers in diffuse large B-cell lymphoma: A system review and meta-analysis.
    Zhao M; Wang L; Wang X; He J; Yu K; Li D
    Tumori; 2024 Aug; 110(4):227-240. PubMed ID: 38183180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
    Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
    Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
    Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX
    Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
    Rajnai H; Heyning FH; Koens L; Sebestyén A; Andrikovics H; Hogendoorn PC; Matolcsy A; Szepesi Á
    Virchows Arch; 2014 Feb; 464(2):229-39. PubMed ID: 24306958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.
    Ma J; Yan S; Zhao Y; Yan H; Zhang Q; Li X
    Front Immunol; 2023; 14():1265255. PubMed ID: 37841254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma.
    Apollonio B; Spada F; Petrov N; Cozzetto D; Papazoglou D; Jarvis P; Kannambath S; Terranova-Barberio M; Amini RM; Enblad G; Graham C; Benjamin R; Phillips E; Ellis R; Nuamah R; Saqi M; Calado DP; Rosenquist R; Sutton LA; Salisbury J; Zacharioudakis G; Vardi A; Hagner PR; Gandhi AK; Bacac M; Claus C; Umana P; Jarrett RF; Klein C; Deutsch A; Ramsay AG
    J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37219943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
    Hontecillas-Prieto L; García-Domínguez DJ; Palazón-Carrión N; Martín García-Sancho A; Nogales-Fernández E; Jiménez-Cortegana C; Sánchez-León ML; Silva-Romeiro S; Flores-Campos R; Carnicero-González F; Ríos-Herranz E; de la Cruz-Vicente F; Rodríguez-García G; Fernández-Álvarez R; Martínez-Banaclocha N; Gumà-Padrò J; Gómez-Codina J; Salar-Silvestre A; Rodríguez-Abreu D; Gálvez-Carvajal L; Labrador J; Guirado-Risueño M; Provencio-Pulla M; Sánchez-Beato M; Marylene L; Álvaro-Naranjo T; Casanova-Espinosa M; Rueda-Domínguez A; Sánchez-Margalet V; de la Cruz-Merino L
    Front Immunol; 2024; 15():1293931. PubMed ID: 38469299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
    Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
    Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed cell death-ligand 1 (PD-L1)
    Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
    Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of circulating neutrophils and lymphocyte subsets in newly diagnosed patients with diffuse large B-cell lymphoma.
    Yang Z; Yu W
    Clin Exp Med; 2023 Jul; 23(3):815-822. PubMed ID: 35939174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.
    Keane C; Law SC; Gould C; Birch S; Sabdia MB; Merida de Long L; Thillaiyampalam G; Abro E; Tobin JW; Tan X; Xu-Monette ZY; Young KH; Gifford G; Gabreilli S; Stevenson WS; Gill A; Talaulikar D; Jain S; Hernandez A; Halliday SJ; Bird R; Cross D; Hertzberg M; Gandhi MK
    Blood Adv; 2020 Apr; 4(7):1367-1377. PubMed ID: 32267932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.
    de Jonge AV; Duetz C; Bruins WSC; Korst CLBM; Rentenaar R; Cosovic M; Eken M; Twickler I; Nijland M; van der Poel MWM; de Heer K; Klerk CPW; Strobbe L; Oosterveld M; Boersma R; Koene HR; Roemer MGM; van Werkhoven E; Chamuleau MED; Mutis T
    Blood Adv; 2024 Mar; 8(5):1094-1104. PubMed ID: 38191686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma.
    Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A
    Discov Med; 2024 Mar; 36(182):621-631. PubMed ID: 38531803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
    Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
    Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3
    Zhang T; Ren T; Song Z; Zhao J; Jiao L; Zhang Z; He J; Liu X; Qiu L; Li L; Zhou S; Meng B; Zhai Q; Ren X; Qian Z; Wang X; Zhang H
    J Immunol Res; 2020; 2020():6968595. PubMed ID: 33178839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High levels of Tim-3
    Zhong W; Liu X; Zhu Z; Li Q; Li K
    Int Immunopharmacol; 2021 Jul; 96():107662. PubMed ID: 33864956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.
    Ansell SM; Stenson M; Habermann TM; Jelinek DF; Witzig TE
    J Clin Oncol; 2001 Feb; 19(3):720-6. PubMed ID: 11157023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma.
    Plonquet A; Haioun C; Jais JP; Debard AL; Salles G; Bene MC; Feugier P; Rabian C; Casasnovas O; Labalette M; Kuhlein E; Farcet JP; Emile JF; Gisselbrecht C; Delfau-Larue MH;
    Ann Oncol; 2007 Jul; 18(7):1209-15. PubMed ID: 17496307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.
    Shi Y; Deng L; Song Y; Lin D; Lai Y; Zhou L; Yang L; Li X
    Int J Hematol; 2018 Sep; 108(3):254-266. PubMed ID: 29748856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.